

DAFTAR PUSTAKA

- Alabdan, N., Elfadol, A.H., Bustami, R., Al-Rajhi, Y.A., dan Al-Sayyari, A.A., 2018, Awareness of Acute Kidney Injury Risk Factors and Perspectives on Its Practice Guidelines, *Hosp Pract*, **46**, 137–143.
- Almanric, K., Marceau, N., Cantin, A., dan Bertin, E., 2017, Risk Factors for Nephrotoxicity Associated with Cisplatin. *Can J Hosp Pharm*, **70** (2), 99–106.
- Alpers, C., dan Fogo, A., 2013. Kidney and Its Collecting System, dalam Kumar, V., K.Abbas, A., C.Aster, J. (Eds.), *Robbins Basic Pathology*, Elsevier Saunders, Philadelphia, 517–549.
- Arunkumar, P., Mukund, H., Radheshyam, N., dan MS Belliyappa, 2011, Clinical Evaluation of Cisplatin Induced Nephrotoxicity Characterized by Electrolyte Disturbances, *Asian J. Res. Pharm. Sci*, **1** (4), 4–100.
- Badan Penelitian dan Pengembangan Kesehatan, 2015, *Stop Kanker*, Kementerian Kesehatan Republik Indonesia Pusat Data dan Informasi Kesehatan.
- Barnett, L.M.A., dan Cummings, B.S., 2018, Nephrotoxicity and Renal Pathophysiology: A Contemporary Perspective, *Toxicol. Sci*, **164** (2), 379–390.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., dan Jemal, A., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, *CA. Cancer J. Clin.*, **68** (6), 394–424.
- Chang, A.R., Grams, M.E., Ballew, S.H., Bilo, H., Correa, A., Evans, M., Gutierrez, O.M., Hosseinpanah, F., Iseki, K., Kenealy, T., Klein, B., Kronenberg, F., Lee, B.J., Li, Y., Miura, K., Navaneethan, S.D., Roderick, P.J., Valdivielso, J.M., Visseren, F.L.J., Zhang, L., Gansevoort, R.T., Hallan, S.I., Levey, A.S., Matsushita, K., Shalev, V., dan Woodward, M., 2019, Adiposity and risk of decline in glomerular filtration rate: Meta-analysis of individual participant data in a global consortium, *BMJ*, **364**, 1-11.
- Chen, T., Postmus, P.E., Ong, T.J., O'Brien, M.E., Gridelli, C., Ko, A., dan Socinski, M.A., 2018, Nab-Paclitaxel/Carboplatin in Elderly Patients with Advanced Squamous Non-Small Cell Lung Cancer: A Retrospective Analysis of a Phase III Trial, *Drug Des. Devel. Ther.*, **12**, 1445–1451.
- Chen, W.Y., Hsiao, C.H., Chen, Y.C., Ho, C.H., Wang, J.J., Hsing, C.H., Wang, H.Y., Kan, W.C., dan Wu, C.C., 2017, Cisplatin Nephrotoxicity Might Have a Sex Difference an Analysis Based on Women's Sex Hormone Changes, *J. Cancer*, **8** (19), 3939–3944.
- Chi-Yuan, H., Bates, D.W., Kuperman, G.J., dan Curhan, G.C., 2001.

Relationship between hematocrit and renal function in men and women. *Kidney Int.* 59, 725–731.

Cohen, G.A., Goffinet, J.A., Donabedian, R.K., dan Conn, H.O., 1976, Observations on Decreased Serum Glutamic Oxalacetic Transaminase (SGOT) Activity in Azotemic Patients, *Ann. Intern. Med.*, **84** (3), 275–280.

Correale, P., Cerretani, D., Remondo, C., Martellucci, I., Marsili, S., La Placa, M., Sciandivasci, A., Paoletti, L., Pascucci, A., Rossi, M., Di Bisceglie, M., Giorgi, G., Gotti, G., dan Francini, G., 2006, A Novel Metronomic Chemotherapy Regimen of Weekly Platinum and Daily Oral Etoposide in High-Risk Non-Small Cell Lung Cancer Patients, *Oncol Rep*, **16** (1), 133–140.

Cullen, M., 2005, The Development of Gemcitabine and Carboplatin in The Treatment of Non-Small-Cell Lung Cancer, *Lung Cancer*, **50** (Suppl. 1), 55–57.

Curtis, L.T., van Berkel, V.H., dan Frieboes, H.B., 2018, Pharmacokinetic/Pharmacodynamic Modeling of Combination-Chemotherapy for Lung Cancer, *J. Theor. Biol.*, **448**, 38–52.

Ferguson, M.A., 2008, Biomarkers of Nephrotoxic Acute Kidney Injury Michael, *Toxicology*, **245** (3), 182–193.

Forgacs, E., Zochbauer-Muller, S., Olah, E., dan Minna, J.D., 2001, Molecular Genetic Abnormalities in The Pathogenesis of Human Lung Cancer, *Pathol.Oncol.Res.*, **7** (1), 6–13.

Fujieda, M., Matsunaga, A., Hayashi, A., Tauchi, H., Chayama, K., dan Sekine, T., 2009, Children's Toxicology From Bench to Bed - Drug-Induced Renal Injury (2): Nephrotoxicity Induced by Cisplatin and Ifosfamide in Children, *J. Toxicol. Sci.*, **34** (SP 2), 51-SP257.

GLOBOCAN, 2018, Indonesia, *Int. Agency Res. cancer*, 1–2.

Gunawan, H., Isnanta, R., Syafri, Z., dan Hasan, R., 2010, Kanker Paru : Sebuah Kajian Singkat, *Ina J CHEST Crit Emerg Med*, **3** (1), 28–32.

Hainaut, P., dan Pfeifer, G.P., 2001, Patterns Of P53 G→T Transversions in Lung Cancers Reflect The Primary Mutagenic Signature of DNA-Damage by Tobacco Smoke, *Carcinogenesis*, **22** (3), 367–374.

Hayuanta, H.H., 2016, Can Hemoglobin-Hematocrit Relationship Be Used to Assess Hydration Status?, *Cermin Dunia Kedokt. J*, **43** (2), 139–142.

International Agency for Research on Cancer, 2018, Latest Global Cancer Data: Cancer Burden Rises To 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018, *Press Release*, 1–3.

- Jemal, A., Siegel, R., Ward, E., Murray, T., J Xu, dan Thun, M., 2007, *Cancer Statistics, CA Cancer J Clin*, **57**, 53–66.
- Jongh, F. de, Veen, R. van, Veltman, S., Wit, R. de, Burg, M. van der, Bent, M. van den, Planting, Ast., Graveland, W., Stoter, G., dan Verweij, J., 2003, Weekly High-Dose Cisplatin is a Feasible Treatment Option : Analysis on Prognostic Factors For Toxicity In 400 Patients, *Br. J. Cancer*, **88** (8), 1199–1206.
- Kementerian Kesehatan Republik Indonesia, 2011, *Pedoman Interpretasi Data Klinik, Kementerian Kesehatan, Republik Indonesia*.
- Kim, S.Y., dan Moon, A., 2012, Drug-Induced Nephrotoxicity and Its Biomarkers, *Biomol. Ther.*, **20** (3), 268–272.
- Knijnenburg, S.L., Jaspers, M.W., van der Pal, H.J., Meeteren, A.Y.S. van, Bouts, A.H., Lieverst, J.A., Bökenkamp, A., Koning, C.C.E., Oldenburger, F., Wilde, J.C.H., van Leeuwen E., F.E., Caron, H.N., dan Kremer, L.C., 2012, Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors, *Clin. J. Am. Soc. Nephrol.*, **7** (9), 1416–1427.
- Koikawa, Y., Tokuda, N., Yasumasu, T., Kumazawa, J., dan Uozumi, J., 1996, The Protective Effect of Methylprednisolone Against Cisplatin-Induced Nephrotoxicity in Patients with Urothelial Tumors, *Int. J. Urol.*, **3**, 343–347.
- Komaki, K., Kusaba, T., Tanaka, M., Kado, H., Shiotsu, Y., Matsui, M., Shiozaki, A., Nakano, H., Ishikawa, T., Fujiwara, H., Konishi, H., Itoh, Y., dan Matoba, S., 2017, Lower Blood Pressure and Risk of Cisplatin Nephrotoxicity : A Retrospective Cohort Study, *BMC Cancer*, **17** (144), 1–8.
- Komite Penanggulangan Kanker Paru Nasional, 2001, *Paduan Penatalaksanaan Kanker Paru, Kementrian Kesehatan, Republik Indonesia*.
- Langer, C.J., Novak, D., 2001, *Thrombocytosis With Cisplatin and Gemcitabine ?* URL www.medscape.com, 10 Maret 2019.
- Latcha, S., Jaimes, E.A., Patil, S., Glezerman, I.G., Mehta, S., dan Flombaum, C.D., 2016, Long-Term Renal Outcomes After Cisplatin Treatment, *Clin. J. Am. Soc. Nephrol.*, **11**, 1173–1179.
- Lemeshow, H.J.S., W, D., Klar, J., dan Lwanga, S.K., 1990, Part 1: Statistical Methods for Sample Size Determination. Adequacy Sample Size Heal, *Stud*, 247.
- Liu, H.E., Bai, K.J., Hsieh, Y.C., Yu, M.C., Lee, C.N., Chang, J.H., Hsu, H.L., Lu, P.C., dan Chen, H.Y., 2014, Multiple Analytical Approaches Demonstrate a Complex Relationship of Genetic and Nongenetic Factors with Cisplatin- and Carboplatin-Induced Nephrotoxicity in Lung Cancer Patients, *Biomed Res. Int.*, **2014**, 1–9.

- Liu, M., Chien, C., dan Burney-Taney, M., 2006, A Pathophysiologic Role for T Lymphocytes in Murine Acute Cisplatin Nephrotoxicity, *J. Am. Soc. Nephrol.*, **17** (3), 765–774.
- McCune, J.S., dan Frieze, D.A., 2008, Lung Cancer, dalam DiPiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 2157–2174, The McGraw-Hill Companies, United States of America..
- Merouani, A., dan Davidson, S., dan RW Schrier, 1997, Increased Nephrotoxicity of Combination Taxol and Cisplatin Chemotherapy in Gynecologic Cancers as Compared to Cisplatin Alone, *Am J Nephrol*, **7** (1), 8–53.
- Miller, R.P., dan Tadagavadi, R.K., Ramesh, G., Reeves, W.B., 2010, Mechanisms of Cisplatin Nephrotoxicity, *Toxins (Basel)*, **2** (11), 2490–2518.
- Miyoshi, T., Misumi, N., Hiraike, M., Mihara, Y., Nishino, T., Tsuruta, M., Kawamata, Y., Hiraki, Y., Kozono, A., dan Ichiki, M., 2016, Risk Factors Associated With Cisplatin-Induced Nephrotoxicity in Patients With Advanced Lung Cancer, *Biol. Pharm. Bull.*, **39** (12), 2009–2014.
- Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E., dan Adjei, A.A., 2008, Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship, *Mayo Clin. Proc.*, **83** (5), 584–594.
- Monleón, A.V., Barrallo, I.G., dan González, I.C., 2017, *Cisplatin Nephrotoxicity in A Patient With Metastatic Testicular Choriocarcinoma : A Case Report and Review of the Literature* **1**(1), 1–5.
- Montoya, J., Luna, H.G., Amparo, J.R., Casasola, C., dan Cristal-Luna, G., 2014, Renal Function of cancer Patients “Fit” for Cisplatin Chemotherapy: Physician Perspective, *Gulf J. Oncolog.*, **1** (16), 64–72.
- Murugan, R., dan Kellim, J., 2011, Acute Kidney Injury : What’s The Prognosis. *Nat Rev Nephrol, Kidney Dis Transpl*, **7** (4), 209–217.
- Musher, K., dan Augustyn, M., 2018, *Serum Enzyme in Patient with Renal Failure*, 24–26.
- National Comprehensive Cancer Network, 2018, *Lung Cancer*, National Comprehensive Cancer Network Inc, Washington.
- National Comprehensive Cancer Network, 2019. *Non-Small Cell Lung Cancer*. In: NCCN Guidelines.
- Naughton, C.A., 2008, Drug-induced nephrotoxicity, *Am. Fam. Physician*, **78** (6), 743–750.
- Nishina, S., Yamazoe, Y., Takeda, M., Chiba, Y., Tamura, T., Tsurutani, J., Nishida, S., Kawakami, H., Nomura, M., Sakiyama, T., Tanaka, K.,

- Okamoto, K., Nakagawa, K., Kidera, Y., Fujiwara, K., dan Kaneda, H., 2014, Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection, *PLoS One*, **9** (7), e101902.
- Ohara, G., Miyazaki, K., Kurishima, K., Kagohashi, K., Ishikawa, H., Satoh, H., dan Hizawa, N., 2011, Safety Creatinine Clearance Level for Platinum Chemotherapy in Lung Cancer Patients, *Oncol. Lett.*, **3** (2), 311–314.
- Pabla, N., dan Dong, Z., 2012, Curtailing Side Effects in Chemotherapy: A Tale Of Pkc δ in Cisplatin Treatment, *Oncotarget*, **3** (1), 107–111.
- Pereira, J.R., Cheng, R., Orlando, M., Kim, J.H., dan Barraclough, H., 2013, Elderly Subset Analysis of Randomized Phase III Study Comparing Pemetrexed Plus Carboplatin with Docetaxel Plus Carboplatin as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer, *Drugs R D*, **13** (4), 289–296.
- Petmitr, S., Wongsommart, D., Chaksangchaichot, P., Pakeetoot, T., Sutinont, P., Sirivaidyapong, P., dan Karalak, A., 2003, Mutational Analysis of Ras Gene Family in Lung Cancer in Thai, *Oncol. Rep.*, **10** (5), 1497–1501.
- Prasetyaningrum, M., Sari, S.P., dan Andalusia, R., 2013, Evaluasi Penurunan Fungsi Ginjal Pasien yang Mendapatkan Cisplatin di Rumah Sakit Kanker Dharmais Jakarta, *Skripsi*, Fakultas Farmasi, Universitas Indonesia.
- Reinmuth, N., 2018, *New Data : New Options for Front-Line Therapy In NSCLC ?*, 1–3.
- Saleena, U. V., Athiyaman, M.S., Donald, F., Vadhiraja, B.M., Prabhu, R., dan Nalini, K., 2012, Evaluation of Urinary Tubular Enzymes for The Detection of Early Kidney Injury Due to Cisplatin Chemotherapy, *Int Biol Med Res*, **3** (3), 2241–2246.
- Schrump, D., Altorki, N., Henschke, C., Carter, D., AT Turrisi, dan Gutherrez, ME., 2005, Non–Small Cell Lung Cancer, dalam VT, J.D., Hellman, S., dan Rosenberg, S. (Eds.), *Cancer: Principles & Practice of Oncology*, 753–809, Philadelphia: Lippincott Williams & Wilkins.
- Sebastian, M., 2009, CHAPTER 38 – Renal Toxicity, *Handb. Toxicol. Chem. Warf. Agents*, 561–574.
- Shirali, A., dan Pazhayattil, G.S., 2014, Drug-Induced Impairment of Renal Function, *Int. J. Nephrol. Renovasc. Dis.*, **7**, 457–468.
- Soni, H., Kaminski, D., Gangaraju, R., dan Adebiyi, A., 2018, Cisplatin-Induced Oxidative Stress Stimulates Renal Fas Ligand Shedding, *Ren. Fail.*, **40** (1), 314–322.

- Szondy, K., Komlosi, Z.I., Mathe, C., Bohacs, A., Lukacsovits, J., Losonczy, G., Horvath, I., Muller, V., dan Duffek, L., 2010, Cisplatin Nephrotoxicity Aggravated by Cardiovascular Disease and Diabetes in Lung Cancer Patients, *Eur. Respir. J.*, **37**, 888–894.
- Thomas, Nolin, dan Himmelfarb, J., 2008, Drug-Induced Kidney Disease. dalam Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., dan Posey, L.M. (Eds.), *Pharmacotherapy A Pathophysiologic Approach*, 795–810, The McGraw-Hill Companies, New York.
- Tsukazan, M.T.R., Vigo, Á., Silva, V.D. da, Barrios, C.H., Rios, J. de O., dan Pinto, J.A. de F., 2017, Lung Cancer: Changes in Histology, Gender, and Age Over The Last 30 Years in Brazil, *J. Bras. Pneumol.*, **43** (4), 363–367.
- Verdiansah, 2009, Pemeriksaan Fungsi Ginjal, *J. Diabetes*, **43** (2), 148–154.
- Yamamoto, Y., Watanabe, K., Matsushita, H., Tsukiyama, I., Matsuura, K., dan Wakatsuki, A., 2017, Multivariate Analysis of Risk Factors for Cisplatin-Induced Nephrotoxicity in Gynecological Cancer, *J. Obstet. Gynaecol. Res.*, **43** (12), 1880–1886.
- Yao, X., Panichpisal, K., Kurtzman, N., dan Nugent, K., 2007, Cisplatin Nephrotoxicity: A Review, *Am. J. Med. Sci.*, **334** (2), 115–124.
- Yilmaz, U.M., Ozdogan, Y., Yilmaz, H., Erol, S., Yalcin, B., Gurlek, U., dan Anar, C., 2015, Chemoradiotherapy-Associated Myelosuppression: A Retrospective Analysis of Risk Factors for Patients with Non-Small Cell Lung Cancer, *Eurasian J. Pulmonol.*, **17** (1), 49–53.
- Yoo, G., Bhat, Z.Y., Ginsburg, K., Treadway, C.K., Sivagnanam, M., Sukari, A., Cadnapaphornchai, P., Chopra, S., Lin, H.-S., dan Doshi, M.D., 2015, Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study, *PLoS One*, **10** (11), 1–9.